Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

The CDMO role

In one sentence

A contract development and manufacturing organization helps develop, make or test a therapeutic product under an agreed scope of work.

The intuition

Imagine commissioning a specialist workshop. You may bring a finished drawing, or ask the workshop to improve both the drawing and the production process. Those are different jobs. The useful question is: who owns each decision and checks the result?

A contract development and manufacturing organization (CDMO) is such a partner for medicines. The analogy stops at treatment choice. A skilled workshop cannot establish that the therapeutic idea benefits patients.

How it works

Define the deliverable. A partner might develop a process, synthesize a molecule, formulate it, fill vials or perform analytical testing. A service label does not establish which of these a particular contract covers. “Development” may include changes that need the product owner's approval. FDA contract-manufacturing guidance

Keep quality responsibilities visible. A quality agreement describes who performs quality activities, handles deviations and communicates changes. It is different from a commercial agreement. For the commercial drug manufacture covered by FDA's guidance, neither party can contract away its applicable good manufacturing practice (GMP) responsibilities. That guidance says similar principles can be valuable for investigational work, although it does not explicitly cover investigational manufacture. FDA scope and responsibilities

Oversee the outsourced work. The product owner's quality system still needs contractor qualification, defined responsibilities and monitoring. Outsourcing a test does not make its result self-interpreting. ICH Q10 pharmaceutical quality system, section 2.7

Control the handoff. Connect the approved design version to materials, records and the resulting lot. A proposed process change raises a manufacturing-comparability question. The relevant assessment depends on the product and change; sharing a contractor or specification does not establish equivalence.

Why it matters in cancer

Personalized vaccines may use a shared process while changing the antigen sequence. Engineered-cell products add recipient and source identity to the handoff. In either case, distinguish the scientific design owner, manufacturing partner, quality reviewer and clinical-program owner. One organization may fill several roles, but the responsibilities still need names.

How the role is checked

Read the agreed scope and quality records. Ask which facility performs each operation, who approves changes, and who reviews failed tests or deviations. A certificate of analysis reports specified measurements. Batch release is the applicable documented disposition; clinical authorization and patient eligibility remain separate questions.

Worked example and practice

A fictional sponsor supplies a vaccine sequence. Its contractor proposes a linker edit and offers a passing identity result on the revised lot.

Try it: What is missing before calling the handoff complete?

Answer: Identify the authorized version and approval of the edit, assess affected product properties, and review the complete applicable quality package. Identity alone does not establish biological activity, access authorization or benefit.

Common confusions

  • A manufacturing partner does not automatically own antigen selection.
  • A quality agreement assigns activities; it does not erase applicable responsibilities.
  • A facility's experience does not establish release of a particular lot.
  • Manufacturing acceptance, clinical-program authorization and evidence of efficacy answer different questions.

Explain it back

“The contractor performs ___; the product owner still needs ___.” One answer: “the agreed activities; oversight and a controlled, reviewable handoff.”

Sources and scope

Source check: October 10, 2026; expert and learner review pending. The example is fictional. These sources explain quality responsibilities, not a particular company's capability or clinical access.

Used in